Abstract:Background: Breast cancer is the leading cause of cancer death in women. The current methods of chemotherapy for breast cancer generally have strong adverse reactions and drug resistance. Therefore, the discovery of novel anti-breast cancer lead compounds is urgently needed. Objective: This study aimed to design and synthesize a series of 2-alkyl substituted fluorinated genistein analogues and evaluate their anti-breast cancer activity. Methods: Target compounds were obtained in a multistep reaction synthesis. The anti-tumor activity of compounds I-1~I-35 was evaluated with MCF-7, MDA-MB-231, MDA-MB-435, and MCF-10A cell lines in vitro, with tamoxifen as the positive control. Molecular docking was used to study the interaction between the synthesized compounds and PI3K-gamma. Results: A series of 2-alkyl substituted fluorinated genistein analogues was designed, synthesized, and screened for their bioactivity. Most of the compounds displayed better selectivity toward breast cancer cell lines as compared to tamoxifen. Among these analogues, I-2, I-3, I-4, I-9, I-15, and I-17 have the strongest selective inhibition of breast cancer cells. Compounds I-10, I-13, I-15, I-17, and I- 33 were found to have significant inhibitory effects on breast cancer cells. Molecular docking studies have shown that these compounds may act as PI3Kγ inhibitors and may further exhibit anti-breast cancer effects. Conclusion: Most of the newly synthesized compounds could highly, selectively inhibit breast cancer cell lines. The experimental results indicate that the synthesized analogs may also have obvious selective inhibitory effects on other malignant proliferation cancer cells.

Antitumor Activity of Novel Fluoro-Substituted (-)-epigallocatechin-3-gallate Analogs

Prodrugs of Fluoro-Substituted Benzoates of EGC As Tumor Cellular Proteasome Inhibitors and Apoptosis Inducers

Epigallocatechin Gallate-Β-lactoglobulin Nanoparticles Improve the Antitumor Activity of EGCG for Inducing Cancer Cell Apoptosis

Evaluation of Proteasome-Inhibitory and Apoptosis-Inducing Potencies of Novel (-)-EGCG Analogs and Their Prodrugs

A Novel Prodrug Of The Green Tea Polyphenol (-)-Epigallocatechin-3-Gallate As A Potential Anticancer Agent

Synthesis And Biological Testing Of Novel Glucosylated Epigallocatechin Gallate (Egcg) Derivatives

Green Tea Catechins: a Fresh Flavor to Anticancer Therapy.

Design, Synthesis, Anti-Tumor Activity, and Molecular Modeling of Quinazoline and Pyrido[2,3-D]Pyrimidine Derivatives Targeting Epidermal Growth Factor Receptor

Green Tea Polyphenols As a Natural Tumour Cell Proteasome Inhibitor.

Potential Effect of EGCG on the Anti-Tumor Efficacy of Metformin in Melanoma Cells

EGCG, green tea polyphenols and their synthetic analogs and prodrugs for human cancer prevention and treatment

New Epigallocatechin Gallate (Egcg) Nanocomplexes Co-Assembled With 3-Mercapto-1-Hexanol And Beta-Lactoglobulin For Improvement Of Antitumor Activity

(−)-Epigallocatechin 3-Gallate Synthetic Analogues Inhibit Fatty Acid Synthase and Show Anticancer Activity in Triple Negative Breast Cancer

Advances In The Antagonism Of Epigallocatechin-3-Gallate In The Treatment Of Digestive Tract Tumors

Green tea and tea polyphenols in cancer prevention.

Epigallocatechin Gallate (EGCG) Is the Most Effective Cancer Chemopreventive Polyphenol in Green Tea

Synthesis and Bio-evaluation of 2-Alkyl Substituted Fluorinated Genistein Analogues Against Breast Cancer.

Novel Perbutyrylated Glucose Derivatives of (–)-Epigallocatechin-3-Gallate Inhibit Cancer Cells Proliferation by Decreasing Phosphorylation of the EGFR: Synthesis, Cytotoxicity, and Molecular Docking

Research Progress of Antitumor Activities of EGCG and its Derivatives

Exploring Pyrimidine-Substituted Curcumin Analogues: Design, Synthesis and Effects on Egfr Signaling

Molecular Targets for Cancer Chemoprevention by (-)-Epigallocatechin Gallate of Green Tea